Fu Guanglei, Liu Wei, Li Yanyan, Jin Yushen, Jiang Lingdong, Liang Xiaolong, Feng Shanshan, Dai Zhifei
Department of Biomedical Engineering, College of Engineering, Peking University , Beijing 100871, P.R. China.
Bioconjug Chem. 2014 Sep 17;25(9):1655-63. doi: 10.1021/bc500279w. Epub 2014 Aug 15.
This paper reported a core-shell nanotheranostic agent by growing Prussian blue (PB) nanoshells of 3-6 nm around superparamagnetic Fe3O4 nanocores for targeted photothermal therapy of cancer under magnetic resonance imaging (MRI) guidance. Both in vitro and in vivo experiments proved that the Fe3O4@PB core-shell nanoparticles showed significant contrast enhancement for T2-weighted MRI with the relaxivity value of 58.9 mM(-1)·s(-1). Simultaneously, the composite nanoparticles exhibited a high photothermal effect under irradiation of a near-infrared laser due to the strong absorption of PB nanoshells, which led to more than 80% death of HeLa cells with only 0.016 mg·mL(-1) of the nanoparticles with the aid of the magnetic targeting effect. Using tumor-bearing nude mice as the model, the near-infrared laser light ablated the tumor effectively in the presence of the Fe3O4@PB nanoparticles and the tumor growth inhibition was evaluated to be 87.2%. Capabilities of MRI, magnetic targeting, and photothermal therapy were thus integrated into a single agent to allow efficient MRI-guided targeted photothermal therapy. Most importantly, both PB and Fe3O4 nanoparticles were already clinically approved drugs, so the Fe3O4@PB nanoparticles as a theranostic nanomedicine would be particularly promising for clinical applications in the human body due to the reliable biosafety.
本文报道了一种核壳型纳米诊疗剂,通过在超顺磁性Fe3O4纳米核周围生长3-6纳米的普鲁士蓝(PB)纳米壳,用于在磁共振成像(MRI)引导下对癌症进行靶向光热治疗。体外和体内实验均证明,Fe3O4@PB核壳纳米粒子在T2加权MRI中显示出显著的对比增强,弛豫率值为58.9 mM(-1)·s(-1)。同时,由于PB纳米壳的强吸收,复合纳米粒子在近红外激光照射下表现出高光热效应,借助磁靶向效应,仅0.016 mg·mL(-1)的纳米粒子就能导致超过80%的HeLa细胞死亡。以荷瘤裸鼠为模型,在Fe3O4@PB纳米粒子存在的情况下,近红外激光有效地消融了肿瘤,肿瘤生长抑制率评估为87.2%。因此,MRI、磁靶向和光热治疗的能力被整合到一种单一制剂中,以实现高效的MRI引导下的靶向光热治疗。最重要的是,PB和Fe3O4纳米粒子均已为临床批准药物,因此Fe3O4@PB纳米粒子作为一种诊疗纳米药物,因其可靠的生物安全性,在人体临床应用中将特别有前景。